Peptic ulcer disease (PUD) continues to be a prevalent gastrointestinal disorder that poses a significant burden on healthcare systems worldwide. Recent advancements in diagnosis, treatment, and management have transformed the approach towards PUD, contributing to improved patient outcomes.
Modern diagnostic tools have revolutionized PUD management. Endoscopy, the gold standard, now benefits from high-definition imaging and narrow-band imaging, enhancing the detection of ulcers and precancerous lesions. Non-invasive tests such as the urea breath test, stool antigen test, and serologic tests have improved the identification of Helicobacter pylori, the leading cause of PUD.
Pharmacotherapy remains at the forefront of PUD management. Proton pump inhibitors (PPIs) continue to be the mainstay, with newer agents providing longer durations of acid suppression and fewer side effects. Antibiotic regimens have also evolved, with quadruple therapy now recommended for H. pylori eradication due to increasing antibiotic resistance. Moreover, the development of gastroprotective agents, such as rebamipide and ecabet, offers additional therapeutic options.
While pharmacotherapy is effective, refractory and complicated PUD may necessitate surgical or endoscopic intervention. Innovations in endoscopic techniques, including endoscopic submucosal dissection and endoscopic mucosal resection, have improved the management of complicated PUD, reducing the need for surgery. However, laparoscopic and robotic surgery have also advanced, offering minimally invasive alternatives when necessary.
Prevention remains key in PUD management. Strategies include H. pylori eradication, avoidance of NSAIDs, and patient education about lifestyle modifications. Telemedicine has emerged as a useful tool for patient education, enabling healthcare professionals to provide personalized advice and monitor adherence to treatment remotely.
In summary, advancements in the management of PUD, from enhanced diagnostic tools to innovative therapeutic strategies, have significantly improved patient outcomes. Continued research and innovation are essential to further optimize PUD management and reduce its global burden.
1.
Discovery reveals protein involved in Parkinson's disease also drives skin cancer
2.
The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.
3.
We Don't Always Know What's 'Best' for Our Patients
4.
New tumor therapy approach reduces costs and side effects while increasing accessibility
5.
Dual-action mRNA vaccine takes aim at aggressive skin cancer
1.
The Evolving Arsenal: A 2025 Review of Antibody-Drug Conjugates and the Future of Precision Oncology
2.
Case Study: Combining Targeted Therapy with Immunotherapy for Metastatic Melanoma
3.
Anion Gap: The Simple Calculation That Reveals Much About Your Health
4.
Contemporary Methods in Hematology Across Clinical Settings
5.
Unlocking the Potential of Cytarabine: A New Era of Cancer Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
5.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation